In recent years, the focus of clinical development has been on immunotherapeutic compounds aimed at clearing brain ...

Figure 1: A new W-shaped structural model of E22G 40-residue beta-amyloid fibrils. RIKEN researchers have shown how the ...

The technology – called Antibody Transport Vehicle (ATV): Amyloid beta – can be used to help amyloid-targeting drugs cross the blood brain barrier (BBB) more effectively, say the partners.

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

The clumping of amyloid beta in the brain to form plaques is one the hallmarks of AD, and the 'amyloid hypothesis' suggests they are a primary driver for the neurodegeneration seen in the disease.

AT-02 is a fusion protein of humanized immunoglobulin G1 with a pan amyloid-reactive peptide that facilitates binding of the antibody to amyloid deposits and subsequent removal. The Food and Drug ...

Maturing Plaques. The oldest plaques (left) contain β-sheets (red) and dense fibrillar cores (blue), while younger plaques (middle) lack dense cores, and the youngest (right) lack either. [Courtesy of ...

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

New research offers hope for delaying Alzheimer’s disease progression by years after initial diagnosis. Alzheimer’s disease is a leading cause of death among those aged 65 or older. As the most common ...

Drs Pavan Brahmbhatt and Amit Agarwal discuss best practices for managing amyloid-related imaging abnormalities in patients ...

An international team led by researchers at the University of Toronto has developed an efficient and robust system, using the C. elegans nematode, to screen for compounds that can stop the growth of ...